A
Aliada Therapeutics
Developing drugs for the treatment of diseases of the central nervous system (cns)
About Aliada Therapeutics
Aliada Therapeutics is a biotechnology company focused on developing innovative therapeutics that advance the delivery of large molecules across the blood-brain barrier. The company's lead program, ALIA 1758, is a differentiated bispecific antibody targeting pyroglutamate amyloid beta and TfR, aimed at effectively clearing amyloid beta plaques from the brain. This approach offers improved convenience and efficacy compared to current treatments. Aliada Therapeutics serves clients in the pharmaceutical and healthcare sectors, particularly those involved in neurology and neurodegenerative diseases. Operating in the biotechnology market, the company employs a business model centered on research and development, clinical trials, and eventual commercialization of its therapeutic solutions. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of approved therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Boston, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
2 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aliada Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aliada Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.